NCT03694197终止4 期
Long Term Safety Study of PRALUENT in Patients With Heterozygous Familial Hypercholesterolemia or With Non-Familial Hypercholesterolemia at High and Very High Cardiovascular Risk and Previously Enrolled in the Neurocognitive Function Trial
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 终止
- 入组人数
- 1,389
- 试验地点
- 5
- 主要终点
- Number of Participants With Adverse Events (AE) After First Administration of Study Drug Through the Last Dose of Study Drug Plus 2 Weeks
研究概览
简要总结
The primary objective of the study was to evaluate the long term safety of PRALUENT in participants with heterozygous familial hypercholesterolemia (heFH) or non-familial hypercholesterolemia (FH) participants at high or very high cardiovascular risk who completed the neurocognitive function study R727-CL-1532 (NCT02957682).
The secondary objectives of the study were:
- To evaluate the effect of PRALUENT on low-density lipoprotein cholesterol (LDL-C)
- To evaluate the effect of PRALUENT on other lipid parameters
- To evaluate the effect of PRALUENT on gonadal steroid hormones
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 40 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants randomized into the neurocognitive function study (R727-CL-1532) who completed treatment and the end of study (EOS) visit with no premature or permanent discontinuation of study drug.
排除标准
- •Significant protocol deviation in the parent study (neurocognitive function study R727-CL-1532: NCT02957682) based on the investigator's or sponsor's judgment, such as noncompliance
- •Any participant who experienced an AE leading to permanent discontinuation from the neurocognitive function study R727-CL-1532 (NCT02957682).
- •Any new condition or worsening of an existing condition which, in the opinion of the investigator or per the PRALUENT local label, would make the participant unsuitable for enrollment or could interfere with the participant participating in or completing the open-label extension (OLE) study
- •Known hypersensitivity to monoclonal antibody or any component of the drug product
- •Pregnant or breastfeeding women
- •Note: Other inclusion/ exclusion criteria apply
研究组 & 干预措施
Open label
Experimental
干预措施: Praluent (Drug)
结局指标
主要结局
Number of Participants With Adverse Events (AE) After First Administration of Study Drug Through the Last Dose of Study Drug Plus 2 Weeks
时间窗: After first administration of study drug through the last dose of study drug plus 2 weeks, up to 80 weeks
An AE is any untoward medical occurrence in a participant administered a study drug which may or may not have a causal relationship with the study drug. AEs include serious adverse events (SAEs), AEs leading to treatment discontinuation, and adverse events of special interest (AESI). AESI include local injection site reactions, general allergic events, elevated alanine aminotransferase (ALT) levels greater than or equal to (≥) 3 upper limit normal (ULN) (if baseline is less than (\<) ULN)/ALT ≥2 x ULN (if baseline ≥ ULN), neurologic events, neurocognitive events (according to Customized Medical Dictionary for Regulatory Activities \[MedDRA\] Query \[CMQ\] by Sponsor grouping and CMQ by FDA grouping), cataract, new onset diabetes (NOD), hepatic disorders, and diabetes mellitus (DM)/diabetic complications.
次要结局
- Change From Baseline in Gonadal Hormones (FSH and LH) for Male Participants Over Time(Up to week 72)
- Percent Change From Baseline in HDL-C Over Time(Up to week 72)
- Fasting Triglycerides (TGs) Values From Baseline Over Time(Up to week 72)
- Percent Change From Baseline in Apo B Over Time(Up to week 72)
- Apolipoprotein-A1 (Apo A1) Values From Baseline Over Time(Up to week 72)
- Non-high-density Lipoprotein Cholesterol (Non-HDL-C) Values From Baseline Over Time(Up to week 72)
- Gonadal Hormone (Follicle Stimulating Hormone [FSH] and Luteinizing Hormone [LH]) Values for Female Participants From Baseline Over Time(Up to week 72)
- Change From Baseline in Gonadal Hormones (FSH and LH) for Female Participants Over Time(Up to week 72)
- Total Cholesterol (Total-C) Values From Baseline Over Time(Up to week 72)
- Percent Change From Baseline in Total-C Over Time(Up to week 72)
- Lipoprotein a (Lp(a)) Values From Baseline Over Time(Up to week 72)
- Percent Change From Baseline in Fasting TGs Over Time(Up to week 72)
- Percent Change From Baseline in Apo A1 Over Time(Up to week 72)
- Gonadal (FSH and LH) Hormone Values for Male Participants From Baseline Over Time(Up to week 72)
- Gonadotropin (Testosterone) Values for Male Participants From Baseline Over Time(Up to week 72)
- Change From Baseline in Alanine Aminotransferase Over Time(Up to week 72)
- Change From Baseline in Aspartate Aminotransferase Over Time(Up to week 72)
- Change From Baseline in Alkaline Phosphatase Over Time(Up to week 72)
- Calculated Low-density Lipoprotein Cholesterol (LDL-C) Values From Baseline Over Time(Up to week 72)
- Percent Change in LDL-C From Baseline Over Time(Up to week 72)
- Percent Change From Baseline in Lp(a) Over Time(Up to week 72)
- Percent Change From Baseline in Non-HDL-C Over Time(Up to week 72)
- High-density Lipoprotein Cholesterol (HDL-C) Values From Baseline Over Time(Up to week 72)
- Apolipoprotein B (Apo B) Values From Baseline Over Time(Up to week 72)
- Total Bilirubin Values From Baseline Over Time(Up to week 72)
- Gonadotropin (Estradiol) Values for Female Participants From Baseline Over Time(Up to week 72)
- Change From Baseline in Gonadotropins (Estradiol) for Female Participants Over Time(Up to week 72)
- Alanine Aminotransferase Values From Baseline Over Time(Up to week 72)
- Aspartate Aminotransferase Values From Baseline Over Time(Up to week 72)
- Change From Baseline in Gonadotropins (Testosterone) for Male Participants Over Time(Up to week 72)
- Alkaline Phosphatase Values From Baseline Over Time(Up to week 72)
- Change From Baseline in Total Bilirubin Over Time(Up to week 72)
研究者
研究点 (5)
Loading locations...
相似试验
Unknown
不适用
Clinical and Radiographic Outcomes of Distal Metatarsal Metaphyseal Osteotomy for Central Primary MetatarsalgiaMetatarsalgia BilateralNCT03639103University of Padova200
进行中（未招募）
1 期
Estudio de seguridad a largo plazo en los pacientes incluidos en el estudio CLARINET con cardiopatía congénita cianosante paliada con derivación sistémica a la arteria pulmonar en los cuales persista la derivación al año de edad--------------------------------------------------------Long-term safety study in patients included in CLARINET study with cyanotic congenital heart disease palliated with a systemic-to-pulmonary artery shunt and for whom the shunt is still in place at one year of age - CLARINET LONG TERMpacientes incluidos en el estudio CLARINET con cardiopatía congénita cianosante paliada con derivación sistémica a la arteria pulmonar en los cuales persista la derivación al año de edad------------------------------------------------------Patients at one year of age who are included in CLARINET, with cyanotic congenital heart disease palliated with a systemic-to-pulmonary artery shunt, and for whom the shunt is still in place.MedDRA version: 8.1Level: LLTClassification code 10019273Term: Heart disease congenitalEUCTR2008-004999-53-ESsanofi-aventis recherche & développement49
已完成
1 期
A Study to Document Long-Term Safety and Continued Benefit of Irinotecan and Carboplatin or Irinotecan in Subjects With Refractory Solid Tumors (Rollover Study -001, -002)Pediatric Solid TumorsNCT00990912Bristol-Myers Squibb20
终止
3 期
Study of Ataluren (PTC124) in Cystic FibrosisCystic FibrosisNCT02107859PTC Therapeutics61
已完成
不适用
A Clinical Trial to Evaluate Long-term Efficacy and Safety of Lozenges Containing Lactobacilli Reuteri (Prodentis™) on GingivitisGingivitisNCT01811316Sunstar Americas62